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Mortality reduction with levosimendan in patients 
with heart failure: Current evidence is underpowered
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It is with great interest that we read the 
meta-analysis by Jaguszewski et al. [1] comparing 
the effects of levosimendan and dobutamine in pa-
tients with heart failure (HF). This meta-analysis 
is relevant and it confirms a possibly preferential 
role for levosimendan in this population of patients 
considering the significant reduction in hospital 
(or 30-day) mortality, as shown by the pooled 
analysis on the 10 included studies. This finding 
is not surprising, since this ino-dilator has shown 
a reduction in mortality for patients with severely 
reduced left ventricular systolic function and/or 
low cardiac output syndrome undergoing cardiac 
surgery. Moreover, levosimendan also reduced the 
need for renal replacement therapy after high-risk 
cardiac surgery [2].
However, before drawing firm conclusions 
on the use of levosimendan in patients with HF, 
an analysis of the robustness of the findings by 
Jaguszewski et al. [1] is needed. Therefore, it was 
thought that the manuscript would greatly benefit 
from the addition of a trial-sequential analysis 
(TSA), which would allow calculation of the re-
quired sample (“information size”), estimating 
the power of the meta-analysis on the reduction 
of mortality by levosimendan, as well as the need 
for further research. 
Hereby, we would like to offer a contribution. 
We imported the same data provided by the authors 
in the TSA Software (Copenhagen Trial Unit’s TSA 
Software®; Copenhagen, Denmark). The informa-
tion size was computed assuming an alpha risk of 
5% with a power of 80%. The estimated mortality 
was computed using weighted averages from the 
included studies (levosimendan 8.4% vs. dobuta-
mine 12.6%). We used a random effect model with 
mortality analyzed as odds ratio (OR). Further 
details on TSA and its interpretation are available 
elsewhere [3]. 
The TSA showed that current evidence is 
severely underpowered to determine whether 
levosimendan reduces mortality in patients with 
HF as compared to dobutamine. Indeed, the ratio 
between number of patients recruited and sample 
needed (n = 2263/8366; 27%; Fig. 1). Therefore, 
more research is certainly warranted on mortality 
in this population of patients.
Another minor (statistical) consideration is on 
the authors’ choice to perform their meta-analysis 
using a fixed effect model, which assumes that the 
true effect is the same across studies. However, it 
is unlikely that all included studies have “identi-
cal” true effect, especially when there is statistical 
heterogeneity (47% in the meta-analysis Jagusze-
wski et al. [1]). In such cases it is advisable to use 
a random effect model, which better balances the 
weights of the included studies [4]. For instance, 
moving from the fixed to the random effect model, 
the weight of the largest study (Mebazaa et al. [5]) 
on the overall results passed from 62% to 28.6%. 
Nonetheless, our consideration does not change 
the meta-analysis results since levosimendan still 
shows significant reductions in mortality also using 
the random effect model (OR: 0.45; 95% confidence 
interval: 0.24–0.84; p = 0.01). 
In summary, in their meta-analysis Jaguszews-
ki et al. [1] showed benefits of levosimendan over 
dobutamine for patients with HF with a significant 
reduction in hospital (or 30-day) mortality. How-
ever, current evidence is severely underpowered 
clinicAl cARDiOlOGY
Cardiology Journal 
2021, Vol. 28, No. 5, 798–799
DOI: 10.5603/CJ.a2021.0078 




LETTER TO THE EDITOR
and further randomized research is required before 
drawing firm conclusions. 
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Figure 1. Trial sequential analysis on hospital (30-day) mortality in patients with heart failure (HF), comparing treat-
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